Thu, Nov 21, 2024
[Archive]
Volume 16, Issue 2 (June 2024 2024)
Iranian Journal of Blood and Cancer 2024, 16(2): 15-23 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Bahadur S, Gupta B, Shukla S, - P, Kalhan S, Gupta M. Evaluating Adverse Events in COVID-19 Recovered Convalescent Plasma Donors: A Comprehensive Analysis. Iranian Journal of Blood and Cancer 2024; 16 (2) :15-23
URL: http://ijbc.ir/article-1-1530-en.html
URL: http://ijbc.ir/article-1-1530-en.html
Evaluating Adverse Events in COVID-19 Recovered Convalescent Plasma Donors: A Comprehensive Analysis
Shalini Bahadur1 
, Bhumika Gupta1 , Shalini Shukla1 , Paridhi - * 2, Shivani Kalhan1 , Madhuvan Gupta1
, Bhumika Gupta1 , Shalini Shukla1 , Paridhi - * 2, Shivani Kalhan1 , Madhuvan Gupta1
1- Department of Pathology, Government Institute of Medical Sciences, Greater Noida
2- Department of Pathology, Government Institute of Medical Sciences, Greater Noida ,paridhi.dr@gmail.com
2- Department of Pathology, Government Institute of Medical Sciences, Greater Noida ,
Abstract: (301 Views)
Background: The emergence of the COVID-19 pandemic prompted the exploration of convalescent plasma therapy (CPT) as a potential treatment modality. This study provides a comprehensive understanding of adverse events in COVID-19-recovered convalescent plasma (CP) donors for optimizing donor safety and refining donation protocols. The aim is to quantify the type and severity of adverse events associated with CP donation.
Materials and Methods: The present one-year retrospective study was undertaken in the blood center of a tertiary care hospital of Western Uttar Pradesh that was a multicentric site in the ICMR Placid trial and a dedicated COVID hospital during the first and second wave in India. Data was analyzed from donor adverse events (DARs) captured during the study period and evaluated for different parameters namely age, gender, body weight, donor status (first-time donor or previous donor), body mass index, blood volume processed, plasma volume collected and lag time between negative RT-PCR report and plasmapheresis. To determine the significance of variations in rates of DARs, Chi-square test was performed (p-value <0.05 considered significant).
Results: A total of 769 donations were performed in the study duration. The maximum donors were between the age group of 26-33 years with 301 donations were from this age group. Out of 769 donations, 648 donors (84.3%) showed no DARs, while 121 donors (15.7%) experienced adverse reactions.
Materials and Methods: The present one-year retrospective study was undertaken in the blood center of a tertiary care hospital of Western Uttar Pradesh that was a multicentric site in the ICMR Placid trial and a dedicated COVID hospital during the first and second wave in India. Data was analyzed from donor adverse events (DARs) captured during the study period and evaluated for different parameters namely age, gender, body weight, donor status (first-time donor or previous donor), body mass index, blood volume processed, plasma volume collected and lag time between negative RT-PCR report and plasmapheresis. To determine the significance of variations in rates of DARs, Chi-square test was performed (p-value <0.05 considered significant).
Results: A total of 769 donations were performed in the study duration. The maximum donors were between the age group of 26-33 years with 301 donations were from this age group. Out of 769 donations, 648 donors (84.3%) showed no DARs, while 121 donors (15.7%) experienced adverse reactions.
Conclusion: Our findings provide essential insights into donor safety, hoping to support and plan future pandemic response strategies against novel infectious diseases.
: Original Article |
Subject:
Adults Hematology & Oncology
Received: 2024/03/9 | Accepted: 2024/06/13 | Published: 2024/06/30
Received: 2024/03/9 | Accepted: 2024/06/13 | Published: 2024/06/30
References
1. Filip R, GheorghitaPuscaselu R, Anchidin-Norocel L, Dimian M, Savage WK. Global Challenges to Public Health Care Systems during the COVID-19 Pandemic: A Review of Pandemic Measures and Problems. J Pers Med. 2022 Aug 7;12(8):1295. doi: 10.3390/jpm12081295. PMID: 36013244; PMCID: PMC9409667. [DOI:10.3390/jpm12081295]
2. Peng HT, Rhind SG, Beckett A. Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis. JMIR Public Health Surveill. 2021 Apr 7;7(4):e25500. doi: 10.2196/25500. Erratum in: JMIR Public Health Surveill. 2021 Jun 30;7(6):e31554. PMID: 33825689; PMCID: PMC8245055. [DOI:10.2196/25500]
3. Abolghasemi H, Eshghi P, Cheraghali AM, ImaniFooladi AA, BoloukiMoghaddam F, Imanizadeh S, MoeiniMaleki M, Ranjkesh M, Rezapour M, Bahramifar A, Einollahi B, Hosseini MJ, Jafari NJ, Nikpouraghdam M, Sadri N, Tazik M, Sali S, Okati S, Askari E, Tabarsi P, Aslani J, Sharifipour E, Jarahzadeh MH, Khodakarim N, Salesi M, Jafari R, Shahverdi S. Clinical efficacy of convalescent plasma for treatment of COVID-19 infections: Results of a multicenter clinical study. TransfusApher Sci. 2020 Oct;59(5):102875. doi: 10.1016/j.transci.2020.102875. Epub 2020 Jul 15. PMID: 32694043; PMCID: PMC7362821. [DOI:10.1016/j.transci.2020.102875]
4. Piyush R, Rajarshi K, Khan R, Ray S. Convalescent plasma therapy: a promising coronavirus disease 2019 treatment strategy. Open Biol. 2020 Sep;10(9):200174. doi: 10.1098/rsob.200174. Epub 2020 Sep 9. PMID: 32898468; PMCID: PMC7536086. [DOI:10.1098/rsob.200174]
5. Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Apr 1;130(4):1545-1548. doi: 10.1172/JCI138003. PMID: 32167489; PMCID: PMC7108922. [DOI:10.1172/JCI138003]
6. Al-Riyami AZ, Schäfer R, van den Berg K, Bloch EM, Estcourt LJ, Goel R, Hindawi S, Josephson CD, Land K, McQuilten ZK, Spitalnik SL, Wood EM, Devine DV, So-Osman C. Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focussed gap analysis with recommendations for future research priorities. Vox Sang. 2021 Jan;116(1):88-98. doi: 10.1111/vox.12973. Epub 2020 Sep 3. PMID: 32542847; PMCID: PMC7891452. [DOI:10.1111/vox.12973]
7. Crocco I, Franchini M, Garozzo G, Gandini AR, Gandini G, Bonomo P, Aprili G. Adverse reactions in blood and apheresis donors: experience from two Italian transfusion centres. Blood Transfus. 2009 Jan;7(1):35-8. doi: 10.2450/2008.0018-08. PMID: 19290078; PMCID: PMC2652234.
8. Kasprisin DO, Glynn SH, Taylor F, Miller KA. Moderate and severe reactions in blood donors. Transfusion. 1992 Jan;32(1):23-6. doi: 10.1046/j.1537-2995.1992.32192116426.x. PMID: 1731431. [DOI:10.1046/j.1537-2995.1992.32192116426.x]
9. Ogata H, Iinuma N, Nagashima K, Akabane T. Vasovagal reactions in blood donors. Transfusion. 1980 Nov-Dec;20(6):679-83. doi: 10.1046/j.1537-2995.1980.20681057157.x. PMID: 7434451. Ref DRUG CON GEN [DOI:10.1046/j.1537-2995.1980.20681057157.x]
10. Ministry of Health and Family Welfare, Government of India. Drugs and Cosmetics Act 1940 and Rules 1945, Amended. [accessed on October 11, 2023]. Available from: https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf
11. Bisht A, Marwaha N, Kaur R, Gupta D, Chhabra R. Haemovigilance Programme of India: Comparative analysis of transfusion reactions reported over a 5-year period through two reporting formats and key recommendations for blood safety. Asian J Transfus Sci. 2020 Jul-Dec;14(2):103-116. doi: 10.4103/ajts.ajts_192_20. Epub 2020 Dec 19. PMID: 33767535; PMCID: PMC7983136. [DOI:10.4103/ajts.ajts_192_20]
12. Narayan S, Shanmugaranjan S, Griffiths A, Roberts D. Vasovagal reactions reported in COVID-19 convalescent plasma donors-NHSBT experience.Transfusion Medicine ; 31(SUPPL 1):10, 2021.
13. He R, Lin H, Xie S, Lv Q, Kong Y, Li L, Xu H, Wang J, Li W, Fang P, Wu Y, Liu Z. Donor tolerability of convalescent plasma donation. J ClinApher. 2021 Jun;36(3):429-436. doi: 10.1002/jca.21882. Epub 2021 Feb 15. PMID: 33587767; PMCID: PMC8013347. [DOI:10.1002/jca.21882]
14. Cho, JH, Rajbhandary, S, van Buren, NL, et al. The safety of COVID-19 convalescent plasma donation: A multi-institutional donor hemovigilance study. Transfusion. 2021; 61: 2668-2676. [DOI:10.1111/trf.16572]
15. Crocco A, D'Elia D. Adverse reactions during voluntary donation of blood and/or blood components. A statistical-epidemiological study. Blood Transfus. 2007 Jul;5(3):143-52. doi: 10.2450/2007.0005-07. PMID: 19204767; PMCID: PMC2535889.
16. Del Fante C, Franchini M, Baldanti F, Percivalle E, Glingani C, Marano G, Mengoli C, Mortellaro C, Viarengo G, Perotti C, Liumbruno GM. A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations. Transfusion. 2021 Mar;61(3):830-838. doi: 10.1111/trf.16208. Epub 2020 Dec 14. PMID: 33231325; PMCID: PMC7753739. [DOI:10.1111/trf.16208]
17. McLeod BC, Price TH, Owen H, Ciavarella D, Sniecinski I, Randels MJ, Smith JW. Frequency of immediate adverse effects associated with apheresis donation. Transfusion. 1998 Oct;38(10):938-43. doi: 10.1046/j.1537-2995.1998.381098440858.x. PMID: 9767744. [DOI:10.1046/j.1537-2995.1998.381098440858.x]
18. Philip J, Sarkar RS, Pathak A. Adverse events associated with apheresis procedures: Incidence and relative frequency. Asian J Transfus Sci. 2013 Jan;7(1):37-41. doi: 10.4103/0973-6247.106730. PMID: 23559763; PMCID: PMC3613659. [DOI:10.4103/0973-6247.106730]
19. Arora D, Garg K, Kaushik A, Sharma R, Rawat DS, Mandal AK. A Retrospective Analysis of Apheresis Donor Deferral and Adverse Reactions at a Tertiary Care Centre in India. J ClinDiagn Res. 2016 Nov;10(11):EC22-EC24. doi: 10.7860/JCDR/2016/20707.8925. Epub 2016 Nov 1. PMID: 28050376; PMCID: PMC5198329.
20. Khade, A. L., Poflee, S. V, Parate, S. N., Gadhave, S. B., Golhar, V. S., &Kumbhalkar, D. T. (2022). Single Donor Plasmapheresis for COVID-19: An Experience from a Tertiary Care Hospital Based Blood Centre. National Journal of Laboratory Medicine, 11(4).
https://doi.org/10.7860/NJLM/2022/55562.2677 [DOI:10.7860/njlm/2022/55562.2677]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
- Iranian Journal of Blood and Cancer
- Journal Tel: +989369936116
- Publisher Tel: +982122275917
- Mail: Info@ijbc.ir
